

**Asymmetric synthesis of  $\alpha,\beta$ -diamino acid derivatives with an aziridine-, azetidine- and  $\gamma$ -lactone-skeleton via Mannich-type additions across  $\alpha$ -chloro-*N*-sulfinylimines†**Gert Callebaut,<sup>‡</sup> Sven Mangelinckx,<sup>§</sup> Loránd Kiss,<sup>b</sup> Reijo Sillanpää,<sup>c</sup> Ferenc Fülöp<sup>b</sup> and Norbert De Kimpe<sup>\*a</sup>

Received 26th September 2011, Accepted 8th December 2011

DOI: 10.1039/c2ob06637h

The efficient asymmetric synthesis of new chiral  $\gamma$ -chloro- $\alpha,\beta$ -diamino acid derivatives *via* highly diastereoselective Mannich-type reactions of *N*-(diphenylmethylene) glycine esters across a chiral  $\alpha$ -chloro-*N*-*p*-toluenesulfinylimine was developed. The influence of the base, LDA or LiHMDS, used for the formation of the glycine enolates, was of great importance for the *anti*-/*syn*-diastereoselectivity of the Mannich-type reaction. The  $\gamma$ -chloro- $\alpha,\beta$ -diamino acid derivatives proved to be excellent building blocks for ring closure towards optically pure *anti*- and *syn*- $\beta,\gamma$ -aziridino- $\alpha$ -amino esters, and subsequent ring transformation into *trans*-3-aminoazetidine-2-carboxylic acid derivatives and  $\alpha,\beta$ -diamino- $\gamma$ -butyrolactones.

**Introduction**

Nature uses  $\alpha$ -amino acid derivatives with a leaving group at the  $\gamma$ -position as versatile building blocks in the biosynthesis of a broad range of biologically important natural products. For example, (*S*)-adenosylmethionine (SAM) is a biological sulfonium compound that is involved in many biological processes. SAM is the second most common co-enzyme in the human body, after ATP, and it is known as the major biological methyl donor in reactions catalyzed by methyltransferases.<sup>1</sup> Enzymological studies have demonstrated that SAM is not only used as a methyl donor in biological reactions, but that SAM is also a precursor for a variety of natural products such as 1-aminocyclopropane-1-carboxylic acid ( $\alpha$ -ACC), precursor of the plant hormone ethylene, *N*-acylhomoserine lactones (AHLs), signal molecules involved in bacterial quorum sensing, and L-azetidine-2-carboxylic acid (L-Aze), a non-proteinogenic amino acid homolog of proline.<sup>1c,2</sup> Besides the biosynthesis of these carbocyclic

and heterocyclic compounds starting from SAM,  $\gamma$ -chloro- $\alpha$ -amino acids also constitute excellent precursors for the preparation of these molecules.<sup>3</sup> Moreover,  $\gamma$ -chloro- $\alpha$ -amino acids are involved in the biosynthesis of a wide range of natural products such as cytotoxicins (apoptosis-inducing *Streptomyces* metabolite),<sup>3a</sup> coronatine (phytoxin),<sup>3b,3c</sup> and bactobolins (antibiotic activity).<sup>4</sup>

Some  $\gamma$ -chloro- $\alpha$ -amino acids are also biologically active as a free amino acid, such as armentomycin, a non-proteinogenic amino acid with antibiotic properties,<sup>3a,5</sup> and 4-chloro-L-threonine, which is biologically active as a serine hydroxymethyltransferase-inhibitor,<sup>3d</sup> and as a herbicidal antimetabolite.<sup>6</sup> 4-Chloro-L-threonine is also a constituent of naturally occurring syringomycins (antifungal compound),<sup>7</sup> and actinomycins (cytotoxic and antibacterial compound).<sup>8</sup>

Next to  $\gamma$ -chloro- $\alpha$ -amino acid derivatives,  $\beta$ -amino acids<sup>9</sup> and  $\alpha,\beta$ -diamino acid derivatives have also gained a lot of attention as non-proteinogenic amino acids for different reasons. Several of these biologically important compounds, such as  $\beta$ -(*N*-oxalyl)-L- $\alpha,\beta$ -diaminopropionic acid (neurotoxin),<sup>10</sup>  $\beta$ -methylamino-L-alanine (neurotoxin),<sup>11</sup> L-quisqualic acid (vermicide),<sup>12</sup> L-mimosine (cell proliferation blocker),<sup>13</sup> and L-willardine (agonist of AMPA and kainate receptor)<sup>14</sup> are found in this group of atypical amino acids.

$\alpha,\beta$ -Diamino acids can also serve as building blocks for the synthesis of new heterocyclic compounds and peptides.<sup>15</sup> Previously published results disclosed the successful racemic synthesis and elaboration of  $\gamma$ -chloro- $\alpha,\beta$ -diamino acid derivatives *via* a Mannich-type addition of 'benzophenone imine glycines' across *N*-(*p*-toluenesulfonyl)  $\alpha$ -chloroaldehydes.<sup>16</sup> Results

<sup>a</sup>Department of Sustainable Organic Chemistry and Technology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, B-9000 Ghent, Belgium. E-mail: norbert.dekimpe@UGent.be; Fax: +32 (0)9 264 62 21; Tel: +32 (0)9 264 59 51


<sup>b</sup>Institute of Pharmaceutical Chemistry, University of Szeged, H-6701 Szeged, P.O. Box 427, Hungary

<sup>c</sup>Department of Chemistry, University of Jyväskylä, Fin-40351 Jyväskylä, Finland


†Electronic supplementary information (ESI) available. See DOI: 10.1039/c2ob06637h

‡Aspirant of the "Institute for the Promotion of Innovation through Science and Technology – Flanders (IWT-Vlaanderen)".

§Postdoctoral Fellow of the Research Foundation – Vlaanderen (FWO)



discussed within the present paper demonstrate the first asymmetric synthesis and elaboration of  $\gamma$ -chloro- $\alpha,\beta$ -diamino acid derivatives, as new building blocks for heterocyclic scaffolds, which incorporate the biologically interesting  $\gamma$ -chloro- $\alpha$ -amino acid moiety as well as the  $\alpha,\beta$ -diamino acid moiety.




## Results and discussion

The new chiral  $\alpha$ -chloro-*N*-sulfinylimine **3** was efficiently prepared by condensation of  $\alpha$ -chloroisobutyraldehyde **1** with (*S*)-(+)-*p*-toluenesulfinamide **2** in dichloromethane in the presence of Ti(OEt)<sub>4</sub> (Scheme 1).<sup>17</sup>

The stereoselective synthesis of chiral azaheterocyclic  $\alpha,\beta$ -diamino acid derivatives was performed *via* a Mannich-type addition of *N*-protected glycine esters **4** across chiral  $\alpha$ -chloro-*N*-sulfinylimine **3** and was optimized by systematically changing the reaction conditions (Scheme 2, Table 1) in the synthesis of  $\gamma$ -chloro- $\alpha,\beta$ -diamino esters **5a**. It was found that the base, LDA or LiHMDS, used for the deprotonation of the glycine ester **4a**, had a dramatic influence on the *syn*- or *anti*-selectivity of the reaction (Table 1).


In a first reaction (Table 1, entry 1), the Mannich-type addition of ethyl glycinate **4a** across chiral  $\alpha$ -chloro-*N*-*p*-toluenesulfinyl isobutyraldimine **3** was performed at  $-78$  °C using five



**Scheme 1** Synthesis of chiral *N*-(2-chloro-2-methylpropylidene) *p*-toluenesulfinamide **3**.

equivalents of LiHMDS. <sup>1</sup>H NMR of the crude reaction mixture indicated that the resulting *syn*- $\gamma$ -chloro- $\alpha,\beta$ -diamino ester **syn-5a** was obtained with good *syn*-selectivity (dr = 93 : 7). The *syn*-adduct **syn-5a** was isolated as a single diastereomer in a yield of 63% after purification by column chromatography and subsequent recrystallization. Repeating the reaction with 1.1 equivalents of LiHMDS (entry 2) led to the formation of *syn*- $\gamma$ -chloro- $\alpha,\beta$ -diamino ester **syn-5a** in an excellent *syn*-selectivity (dr = 99 : 1) after recrystallization in 88% yield. When 1.1 equivalents of the enolate were used, column chromatography to purify the *syn*-adduct **syn-5a** could be avoided which resulted in an improved yield. The use of methyl glycinate **4b** using the same (entry 3) conditions resulted in a similar *syn*-selectivity (dr = 97 : 3) and yield (86%). In the following reaction (entry 4), the Mannich-type addition was performed with 1.1 equivalents of LDA, resulting in  $\gamma$ -chloro- $\alpha,\beta$ -diamino ester **anti-5a** with good *anti*-selectivity (dr = 87 : 13). The *anti*- $\gamma$ -chloro- $\alpha,\beta$ -diamino ester **anti-5a** was obtained in 79% yield as a mixture of two diastereomers (dr 89 : 11) after purification by column chromatography. Unfortunately, the *anti*-adduct **anti-5a** was not crystalline and could not be obtained as a single diastereomer. In order to improve the diastereoselectivity, the reaction was conducted with 1.6 equivalents of LDA (entry 5), according to a procedure as reported for the synthesis of *anti*-ethyl diamino-3-phenylpropanoates from *N*-(benzylidene)-*p*-toluenesulfinamide and glycine enolates.<sup>18a</sup> These conditions led to a slightly better diastereoselectivity (dr 90 : 10), but unfortunately the *anti*- $\gamma$ -chloro- $\alpha,\beta$ -diamino ester **anti-5a** was obtained in a lower yield of 55% as a mixture of two diastereomers (dr 90 : 10) after purification by tedious column chromatography. Next, *tert*-butyl glycinate **4c** was subjected to the Mannich-type reaction conditions with  $\alpha$ -chloro-*N*-*p*-toluenesulfinyl isobutyraldimine **3** using 1.6 equivalents of LDA (entry 6). The resulting *anti*- $\gamma$ -chloro- $\alpha,\beta$ -diamino ester **anti-5c** was obtained with moderate *anti*-selectivity (dr = 72 : 28) and was isolated in 52% yield as a mixture of two diastereomers (dr 81 : 19) after purification by column chromatography.

Both the *syn*- and *anti*-addition products **5** were subsequently cyclized to the corresponding *N*-sulfinylaziridines **6** (Scheme 2) upon treatment with K<sub>2</sub>CO<sub>3</sub> in acetone under reflux in good to excellent isolated yields (73–99%). The *syn*-*N*-sulfinylaziridine **syn-6a** could also be prepared directly in 72% yield *via* a

Scheme 2 Synthesis of *syn*- and *anti*-*N*-sulfinylaziridines **6**.Table 1 Addition of *N*-(diphenylmethylene) glycine esters **4** across *N*-*p*-toluenesulfinylimine **3** producing *syn*- and *anti*-addition products **5**

Entry	Ester	Base	Equiv. Enolate	Time/Temp	<i>syn/anti</i> ratio <sup>a</sup>	Product	Yield (%)
1	<b>4a</b>	LiHMDS	5	15 min, -78 °C	93 : 7	<b>syn-5a</b>	63 <sup>b</sup>
2	<b>4a</b>	LiHMDS	1.1	15 min, -78 °C	99 : 1 <sup>c</sup>	<b>syn-5a</b>	88 <sup>b</sup>
3	<b>4b</b>	LiHMDS	1.1	15 min, -78 °C	97 : 3 <sup>c</sup>	<b>syn-5b</b>	86 <sup>b</sup>
4	<b>4a</b>	LDA	1.1	5 min, -90 °C	13 : 87	<b>anti-5a</b>	79 <sup>d</sup>
5	<b>4a</b>	LDA	1.6	5 min, -90 °C	10 : 90	<b>anti-5a</b>	55 <sup>e</sup>
6	<b>4c</b>	LDA	1.6	5 min, -90 °C	28 : 72	<b>anti-5c</b>	52 <sup>f</sup>
7	<b>4a</b>	LiHMDS	1.1	15 min, -78 °C; 2 h, rt	>99 : 0	<b>syn-6a</b>	72 <sup>b</sup>
8	<b>4a</b>	LDA	1.1	5 min, -90 °C; 2 h, rt	>99 : 0	<b>syn-6a</b>	—

<sup>a</sup> Determined via <sup>1</sup>H NMR of crude reaction mixtures with **syn-5** or **syn-6** as standard <sup>b</sup> Isolated yield of single diastereomer (dr >97 : 3)

<sup>c</sup> Determined via <sup>1</sup>H NMR after recrystallisation of crude reaction mixtures <sup>d</sup> Isolated yield of *anti*- and *syn*-diastereomers (dr 89 : 11) <sup>e</sup> Isolated yield of *anti*- and *syn*-diastereomers (dr 90 : 10) <sup>f</sup> Isolated yield of *anti*- and *syn*-diastereomers (dr 81 : 19)

single-step reaction starting from ethyl glycinate **4a**, if the reaction mixture from the Mannich-type addition across imine **3** after 15 min at -78 °C was subsequently stirred for two hours at room temperature (Table 1, entry 7). This procedure was not applicable for the synthesis of *anti*-*N*-sulfinylaziridines **anti-6** as the *anti*-adducts are the kinetically favored diastereomers which isomerize to the thermodynamically more stable *syn*-isomers (entry 8). The absolute stereochemistry of the *anti*-*N*-*p*-toluenesulfinylaziridine **anti-6a** and *syn*-adduct **syn-5a** were unambiguously determined by means of X-ray diffraction analysis (Fig. 1).

The dramatic influence of the base, LDA or LiHMDS (Scheme 2), on the stereochemical outcome of the Mannich-type reaction across  $\alpha$ -chloro-*N*-sulfinylimine **3** under kinetic conditions (for example -90 °C, 5 min) is rationalized on the basis of the enolate geometry of the anions derived from the

deprotonation of *N*-(diphenylmethylene) glycine esters **4**. As reported in the literature, the enolates obtained *via* deprotonation of *N*-(diphenylmethylene) glycine esters **4** with LDA are expected to have the *Z*-geometry (Scheme 3), which is favoured by intramolecular chelation.<sup>18</sup> As commonly performed in the assignment of enolate geometry, in contrast to conventional *E/Z*-nomenclature, the highest priority designation is allocated to the O-metal group of the enolate substituents. Alternatively, we suggest that upon deprotonation of *N*-(diphenylmethylene) glycine esters **4** with the less basic LiHMDS in THF, a shift towards the formation of the *E*-enolate occurs (Scheme 3). Unfortunately, the enolate geometry could not be determined *via* trapping experiments with TMSCl.<sup>19</sup> Reaction of the *Z*- and *E*-enolates *via* **TS-7a** and **TS-7b** (Scheme 3) results in the formation of **anti-5** and **syn-5**, respectively.<sup>18a</sup>





Fig. 1 X-ray diffraction analysis of *anti*-*N*-sulfinylaziridine *anti*-6a and *syn*-adduct *syn*-5a.




<sup>a</sup>For the assignment of the *E/Z*-geometry of the enolates, the highest priority designation is allocated to the O-metal group of the enolate substituents.


**Scheme 3** Transition state model for the reaction of *Z*- and *E*-enolate of glycine esters **4** in the Mannich-type addition across chiral *N*-(2-chloro-2-methylpropylidene) *p*-toluenesulfinamide **3**.<sup>a</sup>

The *N*-protective groups of *anti*-aziridine **6a** (Scheme 4) were readily removed by treatment with five equivalents of trifluoroacetic acid in acetone/water (2:1) at room temperature for 15 min, resulting in the *N*-deprotected *anti*- $\beta,\gamma$ -aziridino- $\alpha$ -amino ester **8** in 78% yield after a basic workup with  $\text{NH}_4\text{OH}$ .<sup>20</sup>

The *N*-sulfinyl  $\beta,\gamma$ -aziridino moiety of aziridine *anti*-6a could be functionally equivalent to the  $\gamma$ -chloro substituent of natural



**Scheme 4** Deprotection of *anti*-aziridine *anti*-6a with TFA.




**Scheme 5** Synthesis of aziridine *anti-9* and further transformation into 3-amino-1,5-dihydropyrrol-2-one **11**.

**Table 2** Different reaction conditions for the ring transformation of aziridine *anti-9*

Entry	Solvent	Equiv. base	Base	Temp	Time	Result	Yield
1	THF	1	KOtBu	$\Delta$	2.5 h	<b>11</b>	87% <sup>a</sup>
2	THF	1	NaH	$\Delta$	1 h	<b>11</b>	45% <sup>b</sup>
3	EtOH	3	K <sub>2</sub> CO <sub>3</sub>	$\Delta$	22 h	<b>11</b>	98% <sup>a</sup>
4	DMSO	3	K <sub>2</sub> CO <sub>3</sub>	$\Delta$	22 h	Complex mixture	—
5	DMSO	2.5	NaH	80 °C	2 h	<b>11</b>	56% <sup>b</sup>

<sup>a</sup> Yield after precipitation of dihydropyrrol-2-one **11** in diethyl ether <sup>b</sup> Yield after recrystallization from diethyl ether



**Scheme 6** Reaction mechanism for the synthesis of 3-amino-1,5-dihydropyrrol-2-one **11**.


$\gamma$ -chloro- $\alpha$ -amino acids,<sup>3</sup> or the adenosyl-S<sup>+</sup>-CH<sub>3</sub> cation of SAM,<sup>1</sup> in activating the  $\gamma$ -carbon as an electrophile. Eventually, this reactivity could be used in a ring transformation *via* intramolecular *N*-alkylation to the corresponding *trans*- $\beta$ -aminoazetidine-2-carboxylate **10**. The *N*-diphenylmethylene group of *anti-N*-sulfinylaziridine *anti-6a* (Scheme 5) was reduced with NaCNBH<sub>3</sub> in the presence of acetic acid in MeOH, resulting in aziridine *anti-9* containing a nucleophilic  $\alpha$ -amino function (68% yield). Several attempts were made to achieve the ring transformation of *N*-sulfinylaziridine *anti-9* into *trans*- $\beta$ -aminoazetidine-2-carboxylate **10**, albeit without success (Scheme 5, Table 2). A possible explanation for this failure is the poorer electron-withdrawing character of the *p*-toluenesulfinyl group, relative to the *p*-toluenesulfonyl group. Previously, the latter sulfonyl group allowed to achieve an intramolecular ring opening towards the corresponding azetidines.<sup>16b</sup>

An initial attempt using similar reaction conditions as in our previously reported ring transformation into racemic *anti-N*-tosylazetidines, *via* heating in acetonitrile in the presence of one equivalent Et<sub>3</sub>N,<sup>16b</sup> did not result in the formation of *trans*- $\beta$ -aminoazetidine-2-carboxylate **10**. Also, use of more equivalents of triethylamine, other solvents (EtOH, DMSO), and/or

increased reaction times and temperatures, did not lead to the desired conversion. Reaction with one equivalent of BF<sub>3</sub>·Et<sub>2</sub>O at room temperature for 20 h resulted in a complex reaction mixture, in which the *trans*- $\beta$ -aminoazetidine-2-carboxylate **10** was not detected. Also the use of one equivalent LiHMDS led to a complex reaction mixture after heating at reflux for 2.5 h. When aziridine **9** was treated with one equivalent KOtBu in THF at reflux temperature for 2.5 h (Table 2, entry 1), the selective formation of 3-amino-1,5-dihydropyrrol-2-one **11** was observed and isolated in 87% yield.

The proposed reaction mechanism begins with deprotonation at the  $\alpha$ -position of the ester, which leads to an antiperiplanar elimination resulting in ring opening of the aziridine *anti-9* (Scheme 6). The secondary amide group of alkenoate **12** then attacks the ester group leading to  $\gamma$ -lactam **13**. The *p*-toluenesulfinyl group of the ring-closed product **13** was subsequently cleaved by attack of the expelled ethoxide anion, resulting in dihydropyrrol-2-one **11**.

Repeating the reaction with one equivalent NaH for one hour (Table 2, entry 2), also afforded the 3-amino-1,5-dihydropyrrol-2-one **11** however in a lower yield (45%). Performing the reaction in EtOH for 22 h at reflux temperature in the presence of




Scheme 7 Synthesis of aziridines **14** and **15** and further ring transformation to *trans*-*N*-tosylazetidine **16**.

three equivalents of  $K_2CO_3$  (entry 3), afforded the 3-amino-1,5-dihydropyrrol-2-one **11** in an excellent yield of 98%. Repeating the reaction in DMSO led to a complex reaction mixture (entry 4), while the use of 2.5 equivalents of NaH in DMSO at 80 °C for two hours (entry 5), resulted in the 3-amino-1,5-dihydropyrrol-2-one **11** in a yield of 56%. When aziridine *anti*-**9** was treated with one equivalent of DBU in toluene for 24 h at room temperature, no reaction was observed. Reaction of aziridine *anti*-**9** with two equivalents of  $LiClO_4$  in acetonitrile at reflux temperature for 24 h, resulted only in a complex reaction mixture. In an additional series of attempts, a microwave (MW) reactor was used for the ring transformation of aziridine *anti*-**9** to *trans*- $\beta$ -aminoazetidine-2-carboxylate **10**, albeit without success. An initial reaction, performed in acetonitrile at 120 °C for 10 min, led to degradation of the starting material *anti*-**9**. Lowering reaction times and temperatures resulted in degradation or no reaction, without formation of the desired azetidine **10**. In a final attempt, NaI was added to the reaction mixture, but no conversion of the starting material into the envisaged product was achieved.


Subsequently, the *p*-toluenesulfinyl group of *N*-sulfinylaziridine *anti*-**6a** (Scheme 7) was selectively oxidized with 3-chloroperbenzoic acid (mCPBA), resulting in enantiomerically pure *anti*-*N*-sulfonylaziridine **14** containing a strong electron-withdrawing activating group at the aziridine nitrogen. Based on our previously reported ring transformation of racemic *anti*-*N*-

tosylaziridine **15** to racemic *anti*-*N*-tosylazetidine **16**, it was expected that the targeted ring transformation of aziridine **14** to optically pure azetidine **16** should be straightforward.<sup>16b</sup> The *N*-diphenylmethylene moiety of this *anti*-*N*-sulfonylaziridine **14** was subsequently reduced with  $NaCNBH_3$ , resulting in the formation of *anti*-*N*-sulfonylaziridine **15** in 92% yield. It was found that the *anti*-*N*-sulfonylaziridine **15** is an excellent precursor for an easy ring transformation towards *trans*-3-(*N*-tosylamino)azetidine-2-carboxylate **16** via simple heating in acetonitrile at 120 °C for 10 min under microwave (MW) conditions. Noteworthy, the latter transformation as reported for the racemic azetidine **16** required heating at 70 °C in acetonitrile for 20 h under conventional heating conditions.<sup>16b</sup> The enantiomeric excess of *trans*-3-(*N*-tosylamino)azetidine-2-carboxylate **16** (ee > 98%) was determined via chiral HPLC involving comparison to a racemic mixture of azetidine **16** (see Supporting Information).

In a series of follow up experiments, in order to extend the potential applicability of the synthesized 3-aminoazetidine-2-carboxylic acid derivative **16** as building block for the synthesis of peptides, azetidine **16** (Scheme 8) was subjected to several deprotection reactions. In an initial reaction, the ester group was hydrolyzed under basic conditions in 2 M NaOH in aq. methanol, resulting in *trans*-3-(*N*-tosylamino)azetidine-2-carboxylic acid **17** in 69% yield after acidic workup with aqueous HCl. Subsequently, the *N*-(diphenylmethyl)amino group of the azetidine **17** was *N*-deprotected by hydrogenolysis in the presence of



Scheme 8 Synthesis of the deprotected azetidines **17**, **18** and **19**.



Scheme 9 Benzylation and further attempted detosylation of azetidine **16**.


Pd(OH)<sub>2</sub>/C.<sup>21</sup> After precipitation in diethyl ether, the *trans*-3-(*N*-tosylamino)azetidine-2-carboxylic acid **18** was obtained in 92% yield. The hydrogenolysis of the *N*-(diphenylmethyl)amino group could be directly applied on the ethyl ester **16**, affording ethyl 3-(*N*-tosylamino)azetidine-2-carboxylate **19** in 87% yield, also after precipitation from diethyl ether.

Furthermore, some efforts were made to cleave the *N*-tosyl group from *trans*-3-(*N*-tosylamino)azetidine-2-carboxylic ester **16** (Scheme 8), unfortunately without success. In an initial attempt, treatment of azetidine **16** with Mg turnings in MeOH,<sup>22</sup> gave no reaction. When azetidine **16** was treated with sodium or lithium naphthalenide in THF at  $-78\text{ }^{\circ}\text{C}$  or at  $-20\text{ }^{\circ}\text{C}$ ,<sup>23,24</sup> no reaction occurred and the starting material was totally recovered. Performing the reaction with sodium naphthalenide at room temperature for 30 min led to a complex mixture of unidentified products. The use of phenol and 48% HBr in H<sub>2</sub>O,<sup>18,25</sup> or the use of sodium amalgam and disodium hydrogen phosphate in dry methanol,<sup>26</sup> both under reflux conditions gave rise to complex reaction mixtures. Application of conditions reported for the deprotection of tertiary sulfonamides using trimethylsilyl chloride in the presence of sodium iodide,<sup>27</sup> failed also to deprotect azetidine **16**.

The procedure for the deprotection of tertiary sulfonamides using TMSCl in the presence of NaI is reported as straightforward.<sup>27</sup> Thus this strategy was used and azetidine **16** was *N*-benzylated with benzyl bromide in the presence of K<sub>2</sub>CO<sub>3</sub> in DMF (Scheme 9).<sup>28</sup> Next, the *trans*-*N*-benzyl-*N*-tosylazetidine **21** was stirred under reflux for 48 h with 1.5 equivalents TMSCl in the presence of 1.5 equivalents NaI, but unfortunately without formation of the *trans*-(3-*N*-benzylamino)-azetidine **22**.

As the synthesis of the racemic *cis*-isomer of azetidine **16** starting from the *syn*-isomer of aziridine **14** was not possible, but racemic *syn*-aziridine could be transformed into a racemic  $\alpha,\beta$ -diamino- $\gamma$ -butyrolactone,<sup>16b</sup> a similar ring transformation of *syn*-*N*-sulfinylaziridine **syn-6a** to chiral  $\alpha,\beta$ -diamino- $\gamma$ -butyrolactones was evaluated (Scheme 10). (2*R*,3*R*)-2,3-diamino-4,4-dimethylbutyrolactone **23** was prepared *via* acid-mediated synthesis in quantitative yield. The reaction required careful optimization and final reaction conditions involved stirring aziridine **syn-6a** in 0.5 M HCl in H<sub>2</sub>O/EtOAc for 30 min at room temperature (Scheme 10). The optically pure lactone **23** is of interest in further applications towards the synthesis of new  $\beta$ -amino-substituted analogues of *N*-acyl homoserine lactones acting as quorum sensing interfering molecules.<sup>29</sup>

Similarly, *syn*- $\gamma$ -chloro- $\alpha,\beta$ -diamino ester **syn-5a** was treated with 5 equivalents of trifluoroacetic acid in acetone/water (2 : 1) for 15 min (Scheme 11). Following basic workup with NH<sub>4</sub>OH, the *syn*- $\gamma$ -chloro- $\alpha,\beta$ -diamino ester **syn-24** was isolated in 83% yield. The fact that the *N*-sulfinyl group is not removed under these conditions is remarkable, as the deprotection of *anti*-




Scheme 10 Transformation of *syn*-*N*-sulfinylaziridine **syn-6a** into (2*R*,3*R*)-2,3-diamino-butyrolactone **23**.

aziridine **anti-6a** under the same reaction conditions led to unprotected aziridine **8** (Scheme 4).

In conclusion, it was demonstrated that new chiral *syn*- and *anti*- $\gamma$ -chloro- $\alpha,\beta$ -diamino esters are formed in high yield and in excellent diastereomeric ratios *via* stereoselective Mannich-type reactions of *N*-(diphenylmethylene) glycine esters across a chiral  $\alpha$ -chloro-*N*-*p*-toluenesulfinylimine. The base used for the deprotonation of the glycine ester had a dramatic and unexpected influence on the diastereoselectivity of the Mannich-type reaction, with LDA leading selectively to *anti*-diastereomers, whereas the use of LiHMDS leads to *syn*-diastereomers. The  $\gamma$ -chloro- $\alpha,\beta$ -diamino esters proved to be versatile building blocks in asymmetric synthesis as demonstrated by several selective transformations to new *syn*- and *anti*- $\beta,\gamma$ -aziridino- $\alpha$ -amino esters, *trans*-3-aminoazetidine-2-carboxylates and an  $\alpha,\beta$ -diamino- $\gamma$ -butyrolactone.

## General methods

Flame-dried glassware was used for all non-aqueous reactions. Commercially available solvents and reagents were purchased from common chemical suppliers and used without further



Scheme 11 Deprotection of *syn*- $\gamma$ -chloro- $\alpha,\beta$ -diamino ester **syn-5a** with TFA.

purification, unless stated otherwise. Tetrahydrofuran (THF) and diethyl ether (Et<sub>2</sub>O) were freshly distilled under a nitrogen atmosphere from sodium/benzophenone ketyl. Petroleum ether refers to the 40–60 °C boiling fraction. <sup>1</sup>H NMR (300 MHz), <sup>13</sup>C NMR (75 MHz) spectra were recorded in deuterated solvents with tetramethylsilane (TMS, δ = 0 ppm) as internal standard unless specified otherwise. Mass spectra were recorded using a direct inlet system (ESI, 4000 V). IR spectra were obtained from samples in neat form with an ATR (Attenuated Total Reflectance) accessory. Elementary analyses were performed using a CHNS/O elementary analyzer. HRMS analysis was performed using an Agilent 1100 series HPLC coupled to an Agilent 6220 TOF-Mass Spectrometer equipped with ESI/APCI-multimode source. Melting points of crystalline compounds were determined in open-end capillary tubes using a hot stage apparatus and were not corrected. The purification of the reaction mixtures was performed by column chromatography with silica gel (particle size 0.035–0.070 mm, pore diameter ca. 6 nm). Thin layer chromatography (TLC) was performed on glass plates coated with silica gel 60 F<sub>254</sub>, using UV and KMnO<sub>4</sub> as a visualizing agent. (*S<sub>S</sub>*)-*p*-Toluenesulfinamide is commercially available (>98% ee).

## Experimental section

### Synthesis of (*S<sub>S</sub>*)- $\alpha$ -chloro-*N-p*-toluenesulfinyl isobutyraldimine **3**

To a flame dried round-bottomed flask charged with  $\alpha$ -chloroisobutyraldehyde **1** (3.43 g, 32.21 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (100 mL) was added Ti(OEt)<sub>4</sub> (4 equiv, 29.40 g, 128.85 mmol) and (*S<sub>S</sub>*)-*p*-toluenesulfinamide **2** (5.00 g, 32.21 mmol) under nitrogen atmosphere. The reaction mixture was stirred for 18 h at room temperature. After completion, the reaction mixture was poured into water (100 mL) while rapidly stirring. The suspension was filtered over Celite<sup>®</sup> and the solids were washed with CH<sub>2</sub>Cl<sub>2</sub> (2 × 20 mL). Subsequently, the filtrate was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 30 mL) and the combined organic phases were dried (MgSO<sub>4</sub>), filtered and evaporated *in vacuo*. The crude product was purified by column chromatography to yield 7.25 g (29.74 mmol) of pure (*S<sub>S</sub>*)- $\alpha$ -chloro-*N-p*-toluenesulfinyl isobutyraldimine **3**.

### (*S<sub>S</sub>*)- $\alpha$ -chloro-*N-p*-toluenesulfinyl isobutyraldimine **3**

*R<sub>f</sub>* 0.25 (petroleum ether/EtOAc: 5/1). White crystals, yield 92%. Mp 54.6 ± 1.0 °C. IR (cm<sup>-1</sup>):  $\nu_{\max}$  816, 1086, 1071, 1621. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.70 (3H, s), 1.77 (3H, s), 2.41 (3H, s), 7.31 (2H, d, *J* = 8.0 Hz), 7.55 (2H, d, *J* = 8.0 Hz), 8.17 (1H, s). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 21.5, 29.0, 29.1, 66.6, 124.7 (2C), 129.9 (2C), 141.0, 142.0, 165.9. MS (ES, pos. mode) *m/z* (%): 288/290 (100), 244/246 (M + H<sup>+</sup>, 80). HRMS (ES) calcd for C<sub>11</sub>H<sub>14</sub>ClNOS: 244.0557 MH<sup>+</sup>; found: 244.0548 (<1%), 219.1737 (100%).

### Synthesis of (*S<sub>S</sub>*,2*S*,3*R*)-alkyl 2-(diphenylmethyleamino)-4-chloro-4-methyl-3-(*p*-toluenesulfinylamino)pentanoates *anti-5*

The synthesis of (*S<sub>S</sub>*,2*S*,3*R*)-alkyl 2-(diphenylmethyleamino)-4-chloro-4-methyl-3-(*p*-toluenesulfinylamino)pentanoate *anti-5a*

is representative. To a flame dried round-bottomed flask with freshly distilled diisopropylamine (1.1 equiv, 6.76 mmol, 0.67 g) in dry THF (15 mL) was added *n*-BuLi (1.21 equiv, 7.43 mmol, 2.5 M in hexane, 2.97 mL) under nitrogen atmosphere. The reaction mixture was stirred for 5 min at 0 °C and was subsequently cooled to -78 °C. After 5 min, a solution of *N*-(diphenylmethyle) glycine ethyl ester **4a** (1.1 equiv, 6.76 mmol, 1.81 g) in dry THF (5 mL) was slowly added and the resulting solution was stirred for 1 h at -78 °C. After deprotonation, the reaction mixture was cooled to -90 °C and a solution of (*S<sub>S</sub>*)- $\alpha$ -chloro-*N-p*-toluenesulfinyl isobutyraldimine **3** (1.0 equiv, 6.14 mmol, 1.50 g), in dry THF (20 mL) was added dropwise and the reaction mixture was stirred at -90 °C for 5 min. To the reaction mixture was added a saturated solution of NH<sub>4</sub>Cl (40 mL) while stirring was continued at -90 °C for 2 min. The reaction mixture was brought to room temperature, followed by an extraction with EtOAc (3 × 40 mL). The combined organic phases were dried (MgSO<sub>4</sub>), filtered and evaporated *in vacuo*. The crude product was purified by column chromatography to yield 2.48 g (4.85 mmol) of (*S<sub>S</sub>*,2*S*,3*R*)-ethyl 2-(diphenylmethyleamino)-4-chloro-4-methyl-3-(*p*-toluenesulfinylamino)pentanoate *anti-5a* as a 89 : 11 mixture with *syn*-adduct *syn-5a*.

### (*S<sub>S</sub>*,2*S*,3*R*)-Ethyl 2-(diphenylmethyleamino)-4-chloro-4-methyl-3-(*p*-toluenesulfinylamino)pentanoate *anti-5a*

*R<sub>f</sub>* 0.23 (petroleum ether/EtOAc: 3/1). White crystals, yield 79%, dr 89 : 11. Mp 52.7 ± 0.3 °C. IR (cm<sup>-1</sup>):  $\nu_{\max}$  1624, 1731, 3280. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.19 (3H, t, *J* = 7.15 Hz), 1.62 (3H, s), 1.64 (3H, s), 2.37 (3H, s), 3.90 (1H, d × d, *J* = 8.81 Hz, 3.30 Hz), 3.99–4.16 (2H, m), 4.58 (1H, d, *J* = 3.30 Hz), 5.47 (1H, d, *J* = 8.81 Hz), 7.14–7.77 (14H, m). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 14.0, 21.5, 30.6, 30.8, 61.5, 66.4, 67.2, 73.0, 125.6 (2C), 127.8 (2C), 128.2 (2C), 128.7 (2C), 128.9, 129.4 (2C), 129.6 (2C), 130.8, 136.0, 139.3, 141.3, 142.9, 170.7, 172.6. MS (ES, pos. mode) *m/z* (%): 511/513 (M + H<sup>+</sup>, 100). HRMS (ES) calcd for C<sub>28</sub>H<sub>31</sub>ClN<sub>2</sub>O<sub>3</sub>S: 511.1817 MH<sup>+</sup>; found: 511.1825.

### (*S<sub>S</sub>*,2*S*,3*R*)-*tert*-Butyl 2-(diphenylmethyleamino)-4-chloro-4-methyl-3-(*p*-toluenesulfinylamino)pentanoate *anti-5c*

*R<sub>f</sub>* 0.29 (petroleum ether/EtOAc: 3/1). White crystals, yield 52%, dr 81 : 19. Mp 57.2 ± 0.5 °C. IR (cm<sup>-1</sup>):  $\nu_{\max}$  1624, 1725, 3284. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.35 (9H, s), 1.64 (3H, s), 1.69 (3H, s), 2.37 (3H, s), 3.82 (1H, d × d, *J* = 8.53 Hz, 2.5 Hz), 4.44 (1H, d, *J* = 2.20 Hz), 5.62 (1H, d, *J* = 8.81 Hz), 7.15–7.78 (14H, m). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 21.3, 27.8, 30.4, 30.8, 66.6, 67.3, 73.0, 82.2, 125.7 (2C), 127.9 (2C), 128.0 (2C), 128.5 (2C), 128.7, 129.3 (2C), 129.4 (2C), 130.5, 136.0, 139.4, 141.0, 142.5, 169.5, 172.3. MS (ES, pos. mode) *m/z* (%): 539/541 (M + H<sup>+</sup>, 100). HRMS (ES) calcd for C<sub>30</sub>H<sub>35</sub>ClN<sub>2</sub>O<sub>3</sub>S: 539.2130 MH<sup>+</sup>; found: 539.2114.

### Synthesis of (*S<sub>S</sub>*,2*R*,3*R*)-alkyl 2-(diphenylmethyleamino)-4-chloro-4-methyl-3-(*p*-toluenesulfinylamino)pentanoates *syn-5*

The synthesis of (*S<sub>S</sub>*,2*R*,3*R*)-ethyl 2-(diphenylmethyleamino)-4-chloro-4-methyl-3-(*p*-toluenesulfinylamino)pentanoate *syn-5a*



is representative. A solution of *N*-(diphenylmethylene) glycine ethyl ester **4a** (1.1 equiv, 6.76 mmol, 1.81 g) in THF (20 mL) was cooled to  $-78\text{ }^{\circ}\text{C}$  under nitrogen atmosphere. A 1.0 M solution of LiHMDS (1.1 equiv, 6.76 mL, 6.76 mmol) in THF was slowly added and the resulting solution was stirred for 1 h at  $-78\text{ }^{\circ}\text{C}$ . After deprotonation, a solution of (*S*<sub>5</sub>)- $\alpha$ -chloro-*N*-*p*-toluenesulfinyl isobutyraldimine **3** (1.0 equiv, 6.14 mmol, 1.50 g) in THF (20 mL) was added dropwise and the reaction mixture was stirred at  $-78\text{ }^{\circ}\text{C}$  for 15 min. To the reaction mixture was added a saturated solution of NH<sub>4</sub>Cl (40 mL) while stirring at  $-78\text{ }^{\circ}\text{C}$  for 2 min. The reaction mixture was brought to room temperature followed by an extraction with EtOAc (3  $\times$  100 mL). The combined organic phases were dried (MgSO<sub>4</sub>), filtered and evaporated *in vacuo*. The crude product was purified by recrystallization from diethyl ether to yield 2.76 g (5.40 mmol) of pure (*S*<sub>5</sub>,2*R*,3*R*)-ethyl 2-(diphenylmethyleamino)-4-chloro-4-methyl-3-(*p*-toluenesulfinylamino)pentanoate *syn*-**5a**.

**(*S*<sub>5</sub>,2*R*,3*R*)-Ethyl 2-(diphenylmethyleamino)-4-chloro-4-methyl-3-(*p*-toluenesulfinylamino)pentanoate *syn*-**5a****

*R*<sub>f</sub> 0.21 (petroleum ether/EtOAc: 3/1). White crystals, yield 88%. [ $\alpha$ ]<sub>D</sub> +193.8 (*c* 0.6, CHCl<sub>3</sub>). Mp 144.2  $\pm$  1.0  $^{\circ}\text{C}$ . IR (cm<sup>-1</sup>):  $\nu_{\text{max}}$  815, 1070, 1088, 1259, 1621, 1721, 3312. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  1.30 (3H, t, *J* = 7.15 Hz), 1.51 (3H, s), 1.63 (3H, s), 2.45 (3H, s), 4.21–4.38 (3H, m), 4.66 (1H, d, *J* = 1.10 Hz), 5.83 (1H, d, *J* = 8.26 Hz), 7.13–7.19 (2H, m), 7.26–7.46 (8H, m), 7.51–7.54 (2H, m), 7.74 (2H, d, *J* = 8.26 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  14.1, 21.4, 29.0, 30.6, 62.2, 65.6, 67.1, 72.6, 125.7 (2C), 127.1 (2C), 128.1 (2C), 128.6 (2C), 128.9 (2C), 129.0, 129.6 (2C), 130.7, 136.4, 138.8, 141.3, 143.6, 169.6, 171.7. MS (ES, pos. mode) *m/z* (%): 511/513 (M + H<sup>+</sup>, 100). HRMS (ES) calcd for C<sub>28</sub>H<sub>31</sub>ClN<sub>2</sub>O<sub>3</sub>S: 511.1817 MH<sup>+</sup>; found: 511.1838.

**(*S*<sub>5</sub>,2*R*,3*R*)-Methyl 2-(diphenylmethyleamino)-4-chloro-4-methyl-3-(*p*-toluenesulfinylamino)pentanoate *syn*-**5b****

*R*<sub>f</sub> 0.08 (petroleum ether/EtOAc: 4/1). White crystals, yield 86%. [ $\alpha$ ]<sub>D</sub> +224.1 (*c* 1.6, CHCl<sub>3</sub>). Mp 136.4  $\pm$  0.5  $^{\circ}\text{C}$ . IR (cm<sup>-1</sup>):  $\nu_{\text{max}}$  1071, 1092, 1261, 1727, 3319. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  1.51 (3H, s), 1.63 (3H, s), 2.45 (3H, s), 3.83 (3H, s), 4.30 (1H, d  $\times$  d, *J* = 8.53 Hz, 1.38 Hz), 4.70 (1H, d, *J* = 1.10 Hz), 5.83 (1H, d, *J* = 8.81 Hz), 7.13–7.16 (2H, m), 7.28–7.45 (8H, m), 7.50–7.53 (2H, m), 7.74 (2H, d, *J* = 8.26 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  21.4, 29.0, 30.6, 53.1, 65.6, 67.2, 72.4, 125.7 (2C), 127.0 (2C), 128.1 (2C), 128.7 (2C), 128.9 (2C), 129.0, 129.6 (2C), 130.8, 136.4, 138.7, 141.3, 143.5, 170.2, 171.8. MS (ES, pos. mode) *m/z* (%): 497/499 (M + H<sup>+</sup>, 100). HRMS (ES) calcd for C<sub>27</sub>H<sub>29</sub>ClN<sub>2</sub>O<sub>3</sub>S: 497.1660 MH<sup>+</sup>; found: 497.1658.

**Synthesis of (*S*<sub>5</sub>,2'*R*)-alkyl 2-(diphenylmethyleamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfinyl)aziridin-2-yl]acetates **6****

The synthesis of (*S*<sub>5</sub>,2*S*,2'*R*)-ethyl 2-(diphenylmethyleamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfinyl)aziridin-2-yl]acetate *anti*-**6a**

is representative. To a solution of (*S*<sub>5</sub>,2*S*,3*R*)-ethyl 2-(diphenylmethyleamino)-4-chloro-4-methyl-3-(*p*-toluenesulfinylamino)pentanoate *anti*-**5a** (1.50 g, 2.93 mmol) in acetone (35 mL) was added K<sub>2</sub>CO<sub>3</sub> (3.0 equiv, 8.80 mmol, 1.22 g) at room temperature. The reaction mixture was allowed to stir for 24 h at reflux temperature. After 24 h, the K<sub>2</sub>CO<sub>3</sub> was filtered off and the solvent was evaporated *in vacuo*. The resulting oil was redissolved in EtOAc (40 mL) and washed with water (2  $\times$  15 mL). The organic phase was dried (MgSO<sub>4</sub>), filtered and evaporated *in vacuo*. The crude product was purified by column chromatography to yield 1.02 g (2.14 mmol) of (*S*<sub>5</sub>,2*S*,2'*R*)-ethyl 2-(diphenylmethyleamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfinyl)aziridin-2-yl]acetate *anti*-**6a**.

**(*S*<sub>5</sub>,2*S*,2'*R*)-Ethyl 2-(diphenylmethyleamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfinyl)aziridin-2-yl]acetate *anti*-**6a****

*R*<sub>f</sub> 0.25 (petroleum ether/EtOAc: 3/1). White crystals, yield 73%. [ $\alpha$ ]<sub>D</sub> -24.1 (*c* 0.4, CHCl<sub>3</sub>). Mp 103.8  $\pm$  0.2  $^{\circ}\text{C}$ . IR (cm<sup>-1</sup>):  $\nu_{\text{max}}$  1613, 1732. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  1.01 (3H, t, *J* = 7.15 Hz), 1.06 (3H, s), 1.60 (3H, s), 2.36 (3H, s), 3.50 (1H, d, *J* = 8.26 Hz), 3.53–3.66 (2H, m), 3.84 (1H, d, *J* = 8.81 Hz), 7.02–7.05 (2H, m), 7.22 (2H, d, *J* = 8.26 Hz), 7.30–7.41 (6H, m), 7.55 (2H, d, *J* = 8.26 Hz), 7.59–7.63 (2H, m). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  13.8, 20.9, 21.3, 21.7, 42.0, 44.6, 60.8, 65.4, 125.6 (2C), 128.0 (2C), 128.3 (2C), 128.9, 129.0 (2C), 129.2 (2C), 130.6, 135.8, 139.4, 140.8, 143.1, 170.1, 170.9. MS (ES, pos. mode) *m/z* (%): 475 (M + H<sup>+</sup>, 100). Anal. calcd for C<sub>28</sub>H<sub>30</sub>N<sub>2</sub>O<sub>3</sub>S: C 70.86; H 6.37; N 5.90; found: C 71.00; H 6.21; N 5.85.

**(*S*<sub>5</sub>,2*S*,2'*R*)-*tert*-Butyl 2-(diphenylmethyleamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfinyl)aziridin-2-yl]acetate *anti*-**6c****

*R*<sub>f</sub> 0.38 (petroleum ether/EtOAc: 3/1). White crystals, yield 79%, dr 81 : 19. Mp 92.2  $\pm$  0.1  $^{\circ}\text{C}$ . IR (cm<sup>-1</sup>):  $\nu_{\text{max}}$  1149, 1619, 1741. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  1.23 (3H, s), 1.25 (9H, s), 1.60 (3H, s), 2.33 (3H, s), 3.41 (1H, d, *J* = 8.26 Hz), 3.86 (1H, d, *J* = 7.71 Hz), 6.91–7.61 (14H, m). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  21.25, 21.28, 21.8, 27.8 (3C), 42.2, 44.5, 65.5, 81.5, 125.9 (2C), 127.9 (2C), 128.1 (4C), 128.7, 128.9 (2C), 129.2 (2C), 130.3, 135.8, 139.7, 140.7, 143.3, 168.9, 170.1. MS (ES, pos. mode) *m/z* (%): 503 (M + H<sup>+</sup>, 100). Anal. calcd for C<sub>30</sub>H<sub>34</sub>N<sub>2</sub>O<sub>3</sub>S: C 71.68; H 6.82; N 5.57; found: C 72.05; H 6.79; N 5.57.

**(*S*<sub>5</sub>,2*R*,2'*R*)-Ethyl 2-(diphenylmethyleamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfinyl)aziridin-2-yl]acetate *syn*-**6a****

*R*<sub>f</sub> 0.23 (petroleum ether/EtOAc: 3/1). Colourless oil, yield 99%. [ $\alpha$ ]<sub>D</sub> +117.8 (*c* 0.7, CHCl<sub>3</sub>). IR (cm<sup>-1</sup>):  $\nu_{\text{max}}$  695, 1072, 1092, 1624, 1735. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  1.07 (3H, s), 1.24 (3H, t, *J* = 6.9 Hz), 1.60 (3H, s), 1.95 (3H, s), 3.53 (1H, d, *J* = 9.36 Hz), 3.77 (1H, d, *J* = 9.36 Hz), 4.07–4.22 (2H, m), 6.54–6.72 (4H, m), 7.25–7.33 (5H, m), 7.39–7.50 (5H, m). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  14.1, 20.4, 21.2, 22.6, 42.2, 45.4, 61.2, 64.4, 124.6 (2C), 127.7 (2C), 128.0 (4C), 128.3, 129.1 (2C), 129.2 (2C), 130.2, 135.6, 138.9, 141.0, 143.2, 169.8,

170.5. MS (ES, pos. mode)  $m/z$  (%): 475 ( $M + H^+$ , 100). HRMS (ES) calcd for  $C_{28}H_{30}N_2O_3S$ : 475.2050  $MH^+$ ; found: 475.2071.

**(*S*<sub>S</sub>,2*R*,2'*R*)-Methyl 2-(diphenylmethyleamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfinyl)aziridin-2-yl]acetate *syn-6b***

$R_f$  0.26 (petroleum ether/EtOAc: 3/1). White crystals, yield 83%.  $[\alpha]_D^{25} +178.9$  ( $c$  1.6,  $CHCl_3$ ). Mp  $108.0 \pm 0.3$  °C. IR ( $cm^{-1}$ ):  $\nu_{max}$  698, 1070, 1091, 1622, 1741.  $^1H$  NMR (300 MHz,  $CDCl_3$ ):  $\delta$  1.07 (3H, s), 1.60 (3H, s), 1.95 (3H, s), 3.53 (1H, d,  $J = 9.1$  Hz), 3.70 (3H, s), 3.80 (1H, d,  $J = 9.8$  Hz), 6.54–6.86 (4H, m), 7.25–7.35 (5H, m), 7.39–7.50 (5H, m).  $^{13}C$  NMR (75 MHz,  $CDCl_3$ ):  $\delta$  20.4, 21.2, 22.5, 42.2, 45.4, 52.4, 64.3, 124.5 (2C), 127.7 (2C), 128.0 (4C), 128.3, 129.1 (2C), 129.2 (2C), 130.3, 135.5, 138.8, 141.0, 143.2, 170.4, 170.6. MS (ES, pos. mode)  $m/z$  (%): 461 ( $M + H^+$ , 100). HRMS (ES) calcd for  $C_{27}H_{28}N_2O_3S$ : 461.1893  $MH^+$ ; found: 461.1894.

**Synthesis of (*S*<sub>S</sub>,2'*R*)-Ethyl amino-(3,3-dimethylaziridin-2-yl)-acetate **8****

To a solution of (*S*<sub>S</sub>,2*S*,2'*R*)-ethyl 2-(diphenylmethyleamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfinyl)aziridin-2-yl]acetate *anti-6a* (0.50 g, 1.05 mmol) in acetone/ $H_2O$ : 2/1 (30 mL) was added dropwise trifluoroacetic acid (5 equiv, 5.27 mmol, 0.41 mL) at room temperature. The reaction mixture was stirred for 15 min at room temperature and subsequently quenched with  $NH_4OH$  in  $H_2O$  until pH = 10 and concentrated *in vacuo*. The residue was redissolved in water (10 mL) and  $NH_4OH$  was added until pH = 10. The aqueous phase was extracted with  $CH_2Cl_2$  (3  $\times$  10 mL). The combined organic phases were dried ( $MgSO_4$ ), filtered and evaporated *in vacuo*. The crude product was purified by rapid filtration over a short silica column with petroleum ether and the silica was subsequently extracted with  $CH_2Cl_2/MeOH$ : 4/1. The latter phase was filtered and evaporated *in vacuo* to yield 0.14 g (0.82 mmol) of (*S*<sub>S</sub>,2'*R*)-ethyl amino-(3,3-dimethylaziridin-2-yl)-acetate **8**.

**(2*S*,2'*R*)-Ethyl amino-(3,3-dimethylaziridin-2-yl)acetate **8****

Yellowish oil, yield 78%.  $[\alpha]_D^{25} +131.5$  ( $c$  0.9,  $CHCl_3$ ). IR ( $cm^{-1}$ ):  $\nu_{max}$  831, 1027, 1187, 1382, 1729, 2957.  $^1H$  NMR (300 MHz,  $CDCl_3$ ):  $\delta$  1.21 (3H, s), 1.23 (3H, t,  $J = 7.15$  Hz), 1.25 (3H, s), 1.39 (3H, br s), 1.91 (1H, d,  $J = 8.81$  Hz), 3.08 (1H, d,  $J = 8.81$  Hz), 4.16 (2H, q,  $J = 7.15$  Hz).  $^{13}C$  NMR (75 MHz,  $CDCl_3$ ):  $\delta$  14.3, 19.7, 27.2, 35.6, 45.8, 55.6, 61.2, 174.6. MS (ES, pos. mode)  $m/z$  (%): 173 ( $M + H^+$ , 100). HRMS (ES) calcd for  $C_8H_{16}N_2O_2$ : 173.1285  $MH^+$ ; found: 173.1282.

**Synthesis of (*S*<sub>S</sub>,2*S*,2'*R*)-ethyl 2-(diphenylmethylamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfinyl)aziridin-2-yl]acetate **9****

To a solution of (*S*<sub>S</sub>,2*S*,2'*R*)-ethyl 2-(diphenylmethyleamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfinyl)aziridin-2-yl]acetate *anti-6a* (0.37 g, 0.78 mmol) in methanol (4 mL) was added dropwise acetic acid (1 equiv, 0.78 mmol, 0.05 g) at room temperature. Subsequently,  $NaCNBH_3$  (2 equiv, 1.56 mmol, 0.10 g) was added in portions during 5 min. The reaction mixture was

allowed to stir for 6 h at room temperature. After completion, the reaction was quenched with  $H_2O$  (100 equiv, 78 mmol, 1.4 mL) and concentrated *in vacuo*. The resulting precipitate was redissolved in EtOAc (4 mL) and washed with  $H_2O$  (3  $\times$  2 mL). The organic phase was dried ( $MgSO_4$ ), filtered and evaporated *in vacuo*. The crude product was purified by column chromatography to yield 0.25 g (0.53 mmol) of (*S*<sub>S</sub>,2*S*,2'*R*)-ethyl 2-(diphenylmethylamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfinyl)aziridin-2-yl]acetate **9**.

**(*S*<sub>S</sub>,2*S*,2'*R*)-Ethyl 2-(diphenylmethylamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfinyl)aziridin-2-yl]acetate **9****

$R_f$  0.28 (hexane/ $Et_2O$ : 10/1). White crystals, yield 68%.  $[\alpha]_D^{25} +80.6$  ( $c$  1.9,  $CHCl_3$ ). Mp  $99.8 \pm 0.5$  °C. IR ( $cm^{-1}$ ):  $\nu_{max}$  1742, 3287.  $^1H$  NMR (300 MHz,  $CDCl_3$ ):  $\delta$  0.99 (3H, t,  $J = 7.15$  Hz), 1.21 (3H, s), 1.61 (3H, s), 2.22 (1H, br s), 2.37 (3H, s), 2.88 (1H, d,  $J = 9.36$  Hz), 2.91 (1H, d,  $J = 8.81$  Hz), 3.26 (1H, d  $\times$  q,  $J = 11.01$  Hz, 7.15 Hz), 3.61 (1H, d  $\times$  q,  $J = 10.46$  Hz, 7.15 Hz), 4.63 (1H, s), 7.16–7.33 (12H, m), 7.50 (2H, d,  $J = 8.26$  Hz).  $^{13}C$  NMR (75 MHz,  $CDCl_3$ ):  $\delta$  14.0, 20.7, 21.3, 21.8, 41.1, 45.3, 58.5, 60.4, 65.2, 125.3 (2C), 127.0 (2C), 127.3, 127.4, 127.7 (2C), 128.4 (2C), 128.5 (2C), 129.2 (2C), 140.9, 142.1, 142.8, 143.5, 172.7. MS (ES, pos. mode)  $m/z$  (%): 477 ( $M + H^+$ , 100). HRMS (ES) calcd for  $C_{28}H_{32}N_2O_3S$ : 477.2206  $MH^+$ ; found: 477.2210.

**Synthesis of 3-(diphenylmethylamino)-5,5-dimethyl-1,5-dihydropyrrol-2-one **11****

To a solution of (*S*<sub>S</sub>,2*S*,2'*R*)-ethyl 2-(diphenylmethylamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfinyl)aziridin-2-yl]acetate **9** (0.10 g, 0.21 mmol) in ethanol (2 mL) was added  $K_2CO_3$  (3.0 equiv, 0.63 mmol, 0.09 g) at room temperature. The reaction mixture was stirred for 22 h at reflux. Subsequently, the  $K_2CO_3$  was filtered off and the solvent was evaporated *in vacuo*. Precipitation in diethyl ether afforded 0.06 g (0.20 mmol) of 3-(diphenylmethylamino)-5,5-dimethyl-1,5-dihydropyrrol-2-one **11**.

**3-(Diphenylmethylamino)-5,5-dimethyl-1,5-dihydropyrrol-2-one **11****

White crystals, yield 98%. Mp  $213.2 \pm 1.0$  °C. IR ( $cm^{-1}$ ):  $\nu_{max}$  704, 1344, 1650, 1697, 3181, 3359.  $^1H$  NMR (300 MHz,  $CDCl_3$ ):  $\delta$  1.24 (6H, s), 4.52 (1H, br d,  $J = 3.6$  Hz), 4.91 (1H, d,  $J = 1.65$  Hz), 5.25 (1H, d,  $J = 3.6$  Hz), 6.21 (1H, br s), 7.21–7.34 (10H, m).  $^{13}C$  NMR (75 MHz,  $CDCl_3$ ):  $\delta$  27.6, 57.5, 63.7, 115.2, 127.3 (4C), 127.4 (2C), 128.6 (4C), 136.6, 141.8 (2C), 169.0. MS (ES, pos. mode)  $m/z$  (%): 293 ( $M + H^+$ , 100). HRMS (ES) calcd for  $C_{19}H_{20}N_2O$ : 293.1648  $MH^+$ ; found: 293.1651.

**Synthesis of (2*S*,2'*R*)-ethyl 2-(diphenylmethyleamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfonyl)aziridin-2-yl]acetate **14****

To a solution of (*S*<sub>S</sub>,2*S*,2'*R*)-ethyl 2-(diphenylmethyleamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfinyl)aziridin-2-yl]acetate *anti-6a* (1.10 g, 2.32 mmol) in dry  $CH_2Cl_2$  (40 mL) was added mCPBA

(1.1 equiv, 2.55 mmol, 0.44 g) at room temperature. The reaction mixture was allowed to stir for 2 min at room temperature and was subsequently quenched with a saturated solution of NaHCO<sub>3</sub> (20 mL). The organic phase was dried (MgSO<sub>4</sub>), filtered and evaporated *in vacuo*. The crude product was purified by recrystallization from EtOAc to yield 1.02 g (2.09 mmol) of (2*S*,2'*R*)-ethyl 2-(diphenylmethyleneamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfonyl)aziridin-2-yl]acetate **14**. All spectroscopic data were in good agreement with reported data of the racemate of **14**.<sup>16b</sup> White crystals, yield 90%. [ $\alpha$ ]<sub>D</sub> -137.1 (*c* 0.4, CHCl<sub>3</sub>). Mp 128.4 ± 0.5 °C.

#### Synthesis of (2*S*,2'*R*)-ethyl 2-(diphenylmethylamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfonyl)aziridin-2-yl]acetate **15**

To a solution of (2*S*,2'*R*)-ethyl 2-(diphenylmethyleneamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfonyl)aziridin-2-yl]acetate **14** (1.33 g, 2.71 mmol) in methanol (15 mL) was added dropwise acetic acid (1 equiv, 2.71 mmol, 0.16 g) at room temperature. Subsequently, NaCNBH<sub>3</sub> (2 equiv, 5.42 mmol, 0.34 g) was added in portions during 5 min. The reaction mixture was stirred for 6 h at room temperature. After completion, the reaction was quenched with H<sub>2</sub>O (100 equiv, 271 mmol, 4.9 mL) and concentrated *in vacuo*. The resulting precipitate was redissolved in EtOAc (15 mL) and washed with water (3 × 10 mL). The organic phase was dried (MgSO<sub>4</sub>), filtered and evaporated *in vacuo*. The crude product was purified by recrystallization from EtOAc/Et<sub>2</sub>O: 1/1 to yield 1.23 g (2.50 mmol) of (2*S*,2'*R*)-ethyl 2-(diphenylmethylamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfonyl)aziridin-2-yl]acetate **15**. All spectroscopic data were in good agreement with reported data of the racemate of **15**.<sup>16b</sup> White crystals, yield 92%. [ $\alpha$ ]<sub>D</sub> -45.3 (*c* 0.9, CHCl<sub>3</sub>). Mp 95.8 ± 1.0 °C.

#### Synthesis of (2*S*,3*R*)-ethyl 1-diphenylmethyl-4,4-dimethyl-3-(*p*-toluenesulfonylamino)azetidide-2-carboxylate **16**

In a 10 mL microwave vial containing (2*S*,2'*R*)-ethyl 2-(diphenylmethylamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfonyl)aziridin-2-yl]acetate **15** (0.40 g, 0.81 mmol) was added acetonitrile (3 mL). The reaction mixture was stirred vigorously at 120 °C for 10 min. Subsequently, the reaction mixture was concentrated *in vacuo* and the residue was recrystallized from Et<sub>2</sub>O to afford 0.25 g (0.51 mmol) of (2*S*,3*R*)-ethyl 1-diphenylmethyl-4,4-dimethyl-3-(*p*-toluenesulfonylamino)azetidide-2-carboxylate **16**. All spectroscopic data were in good agreement with reported data of the racemate of **16** (ee > 98%).<sup>16b</sup> White crystals, yield 63%. [ $\alpha$ ]<sub>D</sub> +15.6 (*c* 0.2, CHCl<sub>3</sub>). Mp 188.1 ± 0.5 °C.

#### Synthesis of (2*S*,3*R*)-1-diphenylmethyl-4,4-dimethyl-3-(*p*-toluenesulfonylamino)azetidide-2-carboxylic acid **17**

(2*S*,3*R*)-Ethyl 1-diphenylmethyl-4,4-dimethyl-3-(*p*-toluenesulfonylamino)azetidide-2-carboxylate **16** (0.37 g, 0.80 mmol) was dissolved in 2 M NaOH/MeOH: 1/1 (40 mL). The reaction mixture was stirred for 24 h at reflux temperature and subsequently washed with EtOAc (1 × 20 mL). The aqueous phase was brought to pH = 4 with 2 M HCl and extracted with EtOAc

(3 × 20 mL). The combined organic phases were dried (MgSO<sub>4</sub>), filtered and evaporated *in vacuo*. Recrystallization from diethyl ether/hexane: 1/1 afforded 0.24 g (0.52 mmol) of (2*S*,3*R*)-1-diphenylmethyl-4,4-dimethyl-3-(*p*-toluenesulfonylamino)azetidide-2-carboxylic acid **17**.

#### (2*S*,3*R*)-1-Diphenylmethyl-4,4-dimethyl-3-(*p*-toluenesulfonylamino)azetidide-2-carboxylic acid **17**

White crystals, yield 69%. [ $\alpha$ ]<sub>D</sub> +61.0 (*c* 0.5, MeOH). Mp 121.0 ± 0.2 °C. IR (cm<sup>-1</sup>):  $\nu_{\max}$  705, 1092, 1153, 1321, 1454, 1643, 1714, 3062. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  1.19 (3H, s), 1.24 (3H, s), 2.36 (3H, s), 3.65–3.73 (2H, m), 4.88 (1H, s), 6.33 (2H, br s), 7.14–7.36 (10H, m), 7.53 (2H, d, *J* = 7.15 Hz), 7.70 (2H, d, *J* = 7.71 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  16.5, 21.6, 29.7, 56.0, 66.7, 69.3, 70.3, 127.0 (2C), 127.7 (2C), 128.0, 128.6 (3C), 128.8 (2C), 129.1 (2C), 129.9, 136.8, 137.4, 140.2, 143.9, 170.7. MS (ES, pos. mode) *m/z* (%): 465 (M + H<sup>+</sup>, 100). HRMS (ES) calcd for C<sub>26</sub>H<sub>28</sub>N<sub>2</sub>O<sub>4</sub>S: 465.1843 MH<sup>+</sup>; found: 465.1848.

#### Synthesis of (2*S*,3*R*)-4,4-dimethyl-3-(*p*-toluenesulfonylamino)azetidide-2-carboxylic acid derivatives **18** & **19**

The synthesis of (2*S*,3*R*)-4,4-dimethyl-3-(*p*-toluenesulfonylamino)azetidide-2-carboxylic acid **18** is representative. To a solution of (2*S*,3*R*)-1-diphenylmethyl-4,4-dimethyl-3-(*p*-toluenesulfonylamino)azetidide-2-carboxylic acid **17** (0.060 g, 0.13 mmol) in methanol (5 mL) was added Pd(OH)<sub>2</sub>/C (30% mass fraction, 0.018 g) at room temperature. The mixture was stirred for 64 h at room temperature under H<sub>2</sub>-atmosphere (3 bar) and subsequently filtered through a short pad of Celite<sup>®</sup>. The Celite<sup>®</sup> pad was washed exhaustively with CH<sub>2</sub>Cl<sub>2</sub> and the collected organic fractions were evaporated *in vacuo*. Precipitation in diethyl ether afforded 0.035 g (0.12 mmol) of (2*S*,3*R*)-4,4-dimethyl-3-(*p*-toluenesulfonylamino)azetidide-2-carboxylic acid **18**.

#### (2*S*,3*R*)-4,4-Dimethyl-3-(*p*-toluenesulfonylamino)azetidide-2-carboxylic acid **18**

White crystals, yield 92%. [ $\alpha$ ]<sub>D</sub> +66.9 (*c* 0.4, MeOH). Mp 171.0 ± 1.0 °C. IR (cm<sup>-1</sup>):  $\nu_{\max}$  665, 1094, 1159, 1326, 1620, 3063. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD):  $\delta$  1.47 (6H, s), 2.42 (3H, s), 3.87 (1H, d, *J* = 8.0 Hz), 4.27 (1H, d, *J* = 8.0 Hz), 7.38 (2H, d, *J* = 7.71 Hz), 7.76 (2H, d, *J* = 7.71 Hz). <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>OD):  $\delta$  21.3, 21.5, 26.5, 59.4, 60.4, 69.8, 128.2 (2C), 130.9 (2C), 138.9, 145.2, 171.4 (tentative assignment). MS (ES, pos. mode) *m/z* (%): 299 (M + H<sup>+</sup>, 100). HRMS (ES) calcd for C<sub>13</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub>S: 299.1060 MH<sup>+</sup>; found: 299.1066.

#### (2*S*,3*R*)-Ethyl 4,4-dimethyl-3-(*p*-toluenesulfonylamino)azetidide-2-carboxylate **19**

White crystals, yield 87%. [ $\alpha$ ]<sub>D</sub> +54.2 (*c* 0.9, MeOH). Mp 183.6 ± 1.5 °C. IR (cm<sup>-1</sup>):  $\nu_{\max}$  664, 907, 1095, 1167, 1228, 1338, 1732, 2771. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  1.10 (3H, t, *J* = 6.9 Hz), 1.65 (3H, s), 1.68 (3H, s), 1.65–1.68 (1H, br s), 2.42 (3H, s), 3.99–4.13 (3H, m), 5.36 (1H, d, *J* = 7.71 Hz), 7.29 (2H, d,

$J = 8.0$  Hz), 7.80 (2H, d,  $J = 8.0$  Hz), 8.16 (1H, d,  $J = 8.81$  Hz).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CD}_3\text{OD}$ ):  $\delta$  14.2, 20.8, 21.5, 26.0, 57.9, 59.1, 64.0, 72.0, 128.2 (2C), 131.0 (2C), 139.2, 145.4, 167.5. MS (ES, pos. mode)  $m/z$  (%): 327 (M +  $\text{H}^+$ , 100). HRMS (ES) calcd for  $\text{C}_{15}\text{H}_{22}\text{N}_2\text{O}_4\text{S}$ : 327.1373  $\text{MH}^+$ ; found: 327.1379.

#### Synthesis of (2*S*,3*R*)-ethyl 1-diphenylmethyl-4,4-dimethyl-3-[benzyl-(*p*-toluenesulfonyl)amino]azetidene-2-carboxylate 21

To a solution of (2*S*,3*R*)-ethyl 1-diphenylmethyl-4,4-dimethyl-3-(*p*-toluenesulfonylamino)azetidene-2-carboxylate **16** (0.22 g, 0.45 mmol) in DMF (4 mL) was added  $\text{K}_2\text{CO}_3$  (3 equiv, 1.35 mmol, 0.19 g) at room temperature. Subsequently, benzyl bromide (1.4 equiv, 0.63 mmol, 0.11 g) was added dropwise and the reaction mixture was stirred for 3.5 h at room temperature. The reaction mixture was poured in diethyl ether (5 mL) and washed with  $\text{NH}_4\text{Cl}$  in  $\text{H}_2\text{O}$  (2 mL) and brine ( $3 \times 2$  mL). The organic phase was dried ( $\text{MgSO}_4$ ), filtered and evaporated *in vacuo*. The crude product was purified by column chromatography to yield 0.22 g (0.38 mmol) of (2*S*,3*R*)-ethyl 1-diphenylmethyl-4,4-dimethyl-3-[benzyl-(*p*-toluenesulfonyl)amino]azetidene-2-carboxylate **21**.

#### (2*S*,3*R*)-Ethyl 1-diphenylmethyl-4,4-dimethyl-3-[benzyl-(*p*-toluenesulfonyl)amino]azetidene-2-carboxylate 21

$R_f$  0.18 (petroleum ether/EtOAc: 5/1). White crystals, yield 85%.  $[\alpha]_D^{+54.0}$  ( $c$  0.2,  $\text{CHCl}_3$ ). Mp  $165.5 \pm 0.5$  °C. IR ( $\text{cm}^{-1}$ ):  $\nu_{\text{max}}$  671, 695, 706, 1157, 1216, 1332, 1720.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  0.81 (3H, t,  $J = 7.15$  Hz), 0.93 (3H, s), 1.18 (3H, s), 2.39 (3H, s), 3.38–3.49 (1H, m), 3.54–3.65 (1H, m), 3.74 (1H, d,  $J = 7.71$  Hz), 3.90 (1H, d,  $J = 16.2$  Hz), 3.93 (1H, d,  $J = 7.71$  Hz), 4.40 (1H, s), 4.64 (1H, d,  $J = 16.2$  Hz), 7.06–7.37 (15H, m), 7.49 (2H, d,  $J = 7.15$  Hz), 7.64 (2H, d,  $J = 8.26$  Hz).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  13.6, 17.1, 21.5, 29.6, 51.4, 60.4, 62.0, 63.6, 68.6, 69.9, 127.2, 127.4, 127.5 (2C), 127.7, 128.0 (2C), 128.1 (4C), 128.3 (2C), 128.4 (2C), 128.9 (2C), 129.7 (2C), 135.5, 137.7, 140.7, 142.8, 143.6, 171.4. MS (ES, pos. mode)  $m/z$  (%): 583 (M +  $\text{H}^+$ , 100). HRMS (ES) calcd for  $\text{C}_{35}\text{H}_{38}\text{N}_2\text{O}_4\text{S}$ : 583.2625  $\text{MH}^+$ ; found: 583.2620.

#### Synthesis of (R,R)-2,3-diamino-4,4-dimethylbutyrolactone dihydrochloride 23

(*S,S*,2*R*,2'*R*)-ethyl 2-(diphenylmethyleneamino)-2-[3,3-dimethyl-1-(*p*-toluenesulfonyl)aziridin-2-yl]acetate **syn-6a** (0.14 g, 0.29 mmol) was dissolved in a mixture of 0.5 M HCl (aq./EtOAc: 4/1 (10 mL) and the mixture was stirred for 30 min at room temperature. Subsequently, the reaction mixture was concentrated *in vacuo*. Precipitation in diethyl ether afforded 0.06 g (0.28 mmol) of (2*R*,3*R*)-2,3-diamino-4,4-dimethylbutyrolactone dihydrochloride **23**.

#### (2*R*,3*R*)-2,3-Diamino-4,4-dimethylbutyrolactone dihydrochloride 23

White crystals, yield 94%.  $[\alpha]_D^{+12.5}$  ( $c$  0.3, MeOH). Mp  $243.8 \pm 1.5$  °C. IR ( $\text{cm}^{-1}$ ):  $\nu_{\text{max}}$  1042, 1070, 1136, 1273, 1500, 1763,

1787, 2857.  $^1\text{H}$  NMR (300 MHz,  $\text{CD}_3\text{OD}$ , int. ref.  $\text{H}_2\text{O}$ ):  $\delta$  1.48 (3H, s), 1.59 (3H, s), 3.97 (1H, d,  $J = 10.46$  Hz), 4.61 (1H, d,  $J = 10.46$  Hz).  $^{13}\text{C}$  NMR (75 MHz,  $\text{D}_2\text{O}$ , int. ref.  $\text{CH}_3\text{CN}$ ):  $\delta$  21.7, 26.5, 52.3, 57.2, 84.9, 168.1. MS (ES, pos. mode)  $m/z$  (%): 145 (M +  $\text{H}^+ - 2 \times \text{HCl}$ , 100). Anal. calcd for  $\text{C}_6\text{H}_{14}\text{Cl}_2\text{N}_2\text{O}_2$ : C 33.19; H 6.50; N 12.90; found: C 33.55; H 6.51; N 12.66.

#### Synthesis of (*S,S*,2*R*,3*R*)-ethyl 2-amino-4-chloro-4-methyl-3-(*p*-toluenesulfonylamino)pentanoate **syn-24**

To a solution of (*S,S*,2*R*,3*R*)-ethyl 2-(diphenylmethyleneamino)-4-chloro-4-methyl-3-(*p*-toluenesulfonylamino)pentanoate **syn-5a** (0.50 g, 0.98 mmol) in acetone/ $\text{H}_2\text{O}$ : 2/1 (30 mL) was added dropwise trifluoroacetic acid (5 equiv, 4.89 mmol, 0.38 mL) at room temperature. The reaction mixture was stirred for 15 min at room temperature and subsequently quenched with  $\text{NH}_4\text{OH}$  in  $\text{H}_2\text{O}$  until pH = 10 and concentrated *in vacuo*. The residue was redissolved in water (10 mL) and  $\text{NH}_4\text{OH}$  in  $\text{H}_2\text{O}$  was added until pH = 10. The aqueous phase was extracted with  $\text{CH}_2\text{Cl}_2$  ( $3 \times 10$  mL). The combined organic phases were dried ( $\text{MgSO}_4$ ), filtered and evaporated *in vacuo*. The crude product was purified by rapid filtration over a short silica column with petroleum ether and the silica was subsequently extracted with  $\text{CH}_2\text{Cl}_2/\text{MeOH}$ : 4/1. The latter phase was filtered and evaporated *in vacuo* to yield 0.28 g (0.81 mmol) of (*S,S*,2*R*,3*R*)-ethyl 2-amino-4-chloro-4-methyl-3-(*p*-toluenesulfonylamino)pentanoate **syn-24**.

#### (*S,S*,2*R*,3*R*)-Ethyl 2-amino-4-chloro-4-methyl-3-(*p*-toluenesulfonylamino)pentanoate **syn-24**

Yellowish oil, yield 83%.  $[\alpha]_D^{+155.2}$  ( $c$  0.5,  $\text{CHCl}_3$ ). IR ( $\text{cm}^{-1}$ ):  $\nu_{\text{max}}$  811, 1064, 1090, 1224, 1734, 3208.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.36 (3H, t,  $J = 7.15$  Hz), 1.63 (3H, s), 1.69 (2H, br s), 1.74 (3H, s), 2.41 (3H, s), 4.07 (1H, d  $\times$  d,  $J = 9.1$  Hz, 1.10 Hz), 4.17 (1H, d,  $J = 1.10$  Hz), 4.24–4.37 (2H, m), 5.40 (1H, d,  $J = 9.1$  Hz), 7.30 (2H, d,  $J = 8.0$  Hz), 7.63 (2H, d,  $J = 8.0$  Hz).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  14.2, 21.3, 29.2, 30.8, 53.3, 62.2, 65.3, 73.0, 125.4 (2C), 129.5 (2C), 141.4, 142.8, 173.0. MS (ES, pos. mode)  $m/z$  (%): 347 (M +  $\text{H}^+$ , 100). HRMS (ES) calcd for  $\text{C}_{15}\text{H}_{23}\text{ClN}_2\text{O}_3\text{S}$ : 347.1191  $\text{MH}^+$ ; found: 347.1205.

#### Acknowledgements

The authors are indebted to the “Institute for the Promotion of Innovation through Science and Technology – Flanders” (IWT-Vlaanderen) and the Research Foundation – Flanders (FWO – Vlaanderen) for financial support.

#### References

- (a) G. L. Cantoni, *Annu. Rev. Biochem.*, 1975, **44**, 435; (b) A. P. Townsend, S. Roth, H. E. L. Williams, E. Stylianou and N. R. Thomas, *Org. Lett.*, 2009, **11**, 2976; (c) M. Fontecave, M. Atta and E. Mulliez, *Trends Biochem. Sci.*, 2004, **29**, 243.
- F. Couty and G. Evano, *Org. Prep. Proced. Int.*, 2006, **38**, 427.
- (a) M. Ueki, D. P. Galoni Galonić, F. H. Vaillancourt, S. Garneau-Tsodikova, E. Yeh, D. A. Vosburg, F. C. Schroeder, H. Osada and C. T. Walsh, *Chem. Biol.*, 2006, **13**, 1183; (b) F. H. Vaillancourt, E. Yeh, D. A. Vosburg, S. E. O'Connor and C. T. Walsh, *Nature*, 2005, **436**, 1191;

- (29) W. L. Kelly, M. T. Boyne II, E. Yeh, D. A. Vosburg, D. P. Galonić, N. L. Kelleher and C. T. Walsh, *Biochemistry*, 2007, **46**, 359; (d) H. K. Webb and R. G. Matthews, *J. Biol. Chem.*, 1995, **270**, 17204; (e) T.-T. Chen, T. Sanjiki, H. Kato and M. Ohta, *Bull. Chem. Soc. Jpn.*, 1967, **40**, 2398.
- 4 M. R. Seyedsayamdost, J. R. Chandler, J. A. V. Blodgett, P. S. Lima, B. A. Duerkop, K.-I. Oinuma, E. P. Greenberg and J. Clardy, *Org. Lett.*, 2010, **12**, 716.
- 5 K. Liu, R. L. White, J. Y. He and L. C. Vining, *J. Antibiot.*, 1995, **48**, 347.
- 6 H. Yoshida, N. Arai, M. Sugoh, J. Iwabuchi, K. Shiomi, M. Shinose, Y. Tanaka and S. Omura, *J. Antibiot.*, 1994, **47**, 1165.
- 7 L. C. Blasiak, F. H. Vaillancourt, C. T. Walsh and C. L. Drennan, *Nature*, 2006, **440**, 368.
- 8 J. Biltzer, M. Streibel, H.-J. Langer and S. Grond, *Org. Biomol. Chem.*, 2009, **7**, 401.
- 9 (a) F. Fülöp, *Chem. Rev.*, 2001, **101**, 2181; (b) F. Fülöp, T. A. Martinek and G. K. Toth, *Chem. Soc. Rev.*, 2006, **35**, 323; (c) M. A. Gelman and S. H. Gellman, Using constrained  $\beta$ -amino acid residues to control  $\beta$ -peptide shape and function. In *Enantioselective Synthesis of  $\beta$ -Amino Acids*, 2nd ed.; E. Juaristi, V. Soloshonok, ed., John Wiley & Sons, Inc.: Hoboken, NJ, 2005, pp 527–591; (d) F. Gnad and O. Reiser, *Chem. Rev.*, 2003, **103**, 1603; (e) A. Kuhl, M. G. Hahn, M. Dumic and J. Mittendorf, *Amino Acids*, 2005, **29**, 89; (f) J. A. Miller and S. Nguyen, *Mini-Rev. Org. Chem.*, 2005, **2**, 39; (g) M. North, *J. Pept. Sci.*, 2000, **6**, 301; (h) R. M. Ortuno, Enantioselective synthesis of conformationally constrained  $\beta$ -amino acids, In *Enantioselective Synthesis of  $\beta$ -Amino Acids*, 2nd ed.; E. Juaristi, V. Soloshonok, ed., John Wiley & Sons, Inc.: Hoboken, NJ, 2005, pp 117–138.
- 10 (a) S. M. Ross, D. N. Roy and P. S. Spencer, *J. Neurochem.*, 1989, **53**, 710; (b) M. I. Sabri, B. Lystrup, D. N. Roy and P. S. Spencer, *J. Neurochem.*, 1995, **65**, 1842; (c) M. Abraham and S. M. Abay, *Pharmacology*, 2009, 381; (d) Z.-Y. Yan, P. S. Spencer, Z.-X. Li, Y.-M. Liang, Y.-F. Wang, C.-Y. Wang and F.-M. Li, *Phytochemistry*, 2006, **67**, 107; (e) L. A. Chase, N. L. Peterson and J. F. Koerner, *Toxicol. Appl. Pharmacol.*, 2007, **219**, 1; (f) F. Lambein, Y.-H. Kuo, K. Kusama-Eguchi and F. Ikegami, *ARKIVOC*, 2007, 45; (g) M. Van Moorhem, F. Lambein and L. Leybaert, *Food Chem. Toxicol.*, 2011, **49**, 550.
- 11 (a) A. Copani, P. L. Canonico, M. V. Catania, E. Aronica, V. Bruno, E. Ratti, F. T. M. van Amsterdam, G. Gaviraghi and F. Nicoletti, *Brain Res.*, 1991, **558**, 79; (b) A. Vega and E. A. Bell, *Phytochemistry*, 1967, **6**, 759; (c) A. J. Davis, G. E. Hawkes, P. O'Brien, G. Wang and P. B. Nunn, *J. Chem. Res. (S)*, 1991, 84.
- 12 (a) N. Subasinghe, M. Schulte, R. J. Roon, J. F. Koerner and R. L. Johnson, *J. Med. Chem.*, 1992, **35**, 4602; (b) M. B. Hermit, J. R. Greenwood and H. Bräuner-Osborne, *J. Biol. Chem.*, 2004, **279**, 34811.
- 13 (a) H.-C. Chang, T.-H. Lee, L.-Y. Chuang, M.-H. Yen and W.-C. Hung, *Cancer Lett.*, 1999, **145**, 1; (b) P. S. Dobbin, R. C. Hider, A. D. Hall, P. D. Taylor, P. Sarpong, J. B. Porter, G. Xiao and D. van der Helm, *J. Med. Chem.*, 1993, **36**, 2448.
- 14 (a) A. P. Martinez and W. W. Lee, *J. Org. Chem.*, 1965, **30**, 317; (b) D. E. Jane, K. Hoo, R. Kamboj, M. Deverill, D. Bleakman and A. Mandelzys, *J. Med. Chem.*, 1997, **40**, 3645; (c) A. J. H. Nollet and U. K. Pandit, *Tetrahedron*, 1969, **25**, 5983.
- 15 (a) A. Viso, R. Fernández de la Pradilla, A. Garcia and A. Flores, *Chem. Rev.*, 2005, **105**, 3167; (b) A. Viso, R. Fernández de la Pradilla, M. Tortosa, A. Garcia and A. Flores, *Chem. Rev.*, 2011, **111**, PR1; (c) C. Palomo, J. M. Aizpurua, I. Ganboa and M. Oiarbide, *Amino Acids*, 1999, **16**, 321.
- 16 (a) L. Kiss, S. Manginckx, R. Sillanpää, F. Fülöp and N. De Kimpe, *J. Org. Chem.*, 2007, **72**, 7199; (b) L. Kiss, S. Manginckx, F. Fülöp and N. De Kimpe, *Org. Lett.*, 2007, **9**, 4399.
- 17 F. A. Davis, Y. Zhang, Y. Andemichael, T. Fang, D. L. Fanelli and H. Zhang, *J. Org. Chem.*, 1999, **64**, 1403.
- 18 (a) F. A. Davis and J. H. Deng, *Org. Lett.*, 2004, **6**, 2789; (b) F. A. Davis, Y. Zhang and H. Qiu, *Org. Lett.*, 2007, **9**, 833; (c) J. Ezquerria, C. Pedregal, I. Merino, J. Florez, J. Barluenga, S. Garcia-Granda and M.-A. Llorca, *J. Org. Chem.*, 1999, **64**, 6554.
- 19 M. B. Gillies, J. E. Tønder, D. Tanner and P.-O. Norrby, *J. Org. Chem.*, 2002, **67**, 7378.
- 20 (a) F. A. Davis, P. Zhou and G. V. Reddy, *J. Org. Chem.*, 1994, **59**, 3243; (b) F. A. Davis, H. Liu, P. Zhou, T. Fang, G. V. Reddy and Y. Zhang, *J. Org. Chem.*, 1999, **64**, 7559.
- 21 S. P. Allwein, E. A. Secord, A. Martins, J. V. Mitten, T. D. Nelson, M. H. Kress and U. H. Dolling, *Synlett*, 2004, 2489.
- 22 J. Hernández-Toribio, R. Gómez Arrayás and J. C. Carretero, *Chem.–Eur. J.*, 2010, **16**, 1153.
- 23 S. C. Bergmeier and P. P. Seth, *Tetrahedron Lett.*, 1999, **40**, 6181.
- 24 (a) E. Alonso, D. J. Ramón and M. Yus, *Tetrahedron*, 1997, **53**, 14355; (b) J. M. Concellón, H. Rodríguez-Solla and C. Simal, *Org. Lett.*, 2008, **10**, 4457.
- 25 (a) F. A. Davis, H. Liu and G. V. Reddy, *Tetrahedron Lett.*, 1996, **37**, 5473; (b) Y. Pei, K. Brade, E. Brulé, L. Hagberg, F. Lake and C. Moberg, *Eur. J. Org. Chem.*, 2005, 2835.
- 26 K. Ajayi, V. V. Thakur, R. C. Lapo and S. Knapp, *Org. Lett.*, 2010, **12**, 2630.
- 27 G. Sabitha, B. V. S. Reddy, S. Abraham and J. S. Yadav, *Tetrahedron Lett.*, 1999, **40**, 1569.
- 28 H.-D. Arndt, R. Welz, S. Müller, B. Ziemer and U. Koert, *Chem.–Eur. J.*, 2004, **10**, 3945.
- 29 (a) M. Teplitski, U. Mathesius and K. P. Rumbaugh, *Chem. Rev.*, 2011, **111**, 100; (b) M. E. Mattmann and H. E. Blackwell, *J. Org. Chem.*, 2010, **75**, 6737.